In Brief: FDA Obstetrics and Gynecology Devices Panel
This article was originally published in The Gray Sheet
FDA Obstetrics and Gynecology Devices Panel: Meeting Feb. 26 at 8:30 a.m. at the Center for Devices and Radiological Health, 9200 Corporate Blvd., Rockville, Maryland, to discuss "general issues relating to a premarket approval application for a tubal occlusion device for female sterilization," according to a Feb. 8 Federal Register notice. The committee also will be presented with data from the Centers for Disease Control and Prevention on the U.S. Collaborative Review of Sterilization ("CREST") study. For information contact FDA's Alfred Montgomery at 301/594-1180...
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.